Literature DB >> 8450039

Arylsulfatase B-deficient mucopolysaccharidosis in rats.

M Yoshida1, J Noguchi, H Ikadai, M Takahashi, S Nagase.   

Abstract

A rat colony with mucopolysaccharidosis VI was established and the clinical, pathological, and biochemical features were characterized. Affected rats had facial dysmorphia, dysostosis multiplex, and increased urinary excretion of glucosaminoglycans (GAGs). Ultrastructural studies revealed storage of GAGs throughout the reticuloendothelial cells, cartilage, and other connective tissues, but no deposition was observed in the nervous system. Biochemical analyses demonstrated that the excreted GAG was dermatan sulfate and the activity of hepatic arylsulfatase B was < 5% of the normal mean value. Pedigree analysis showed that the phenotype was inherited as an autosomal recessive single trait. The availability of a rat model of human mucopolysaccharidosis VI should permit the development and evaluation of various strategies to treat the human disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8450039      PMCID: PMC288065          DOI: 10.1172/JCI116268

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Alpha-L-iduronidase deficiency in a cat: a model of mucopolysaccharidosis I.

Authors:  M E Haskins; P F Jezyk; R J Desnick; S K McDonough; D F Patterson
Journal:  Pediatr Res       Date:  1979-11       Impact factor: 3.756

2.  A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice.

Authors:  C Vogler; E H Birkenmeier; W S Sly; B Levy; C Pegors; J W Kyle; W G Beamer
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

3.  Canine alpha-L-iduronidase deficiency. A model of mucopolysaccharidosis I.

Authors:  R M Shull; R J Munger; E Spellacy; C W Hall; G Constantopoulos; E F Neufeld
Journal:  Am J Pathol       Date:  1982-11       Impact factor: 4.307

4.  Comparison of glycogen phosphorylase kinases of various rat tissues.

Authors:  T Taira; R Kii; K Sakai; H Tabuchi; S Takimoto; S Nakamura; J Takahashi; E Hashimoto; H Yamamura; Y Nishizuka
Journal:  J Biochem       Date:  1982-03       Impact factor: 3.387

5.  Mucopolysaccharidosis type VI: identification of three mutations in the arylsulfatase B gene of patients with the severe and mild phenotypes provides molecular evidence for genetic heterogeneity.

Authors:  W D Jin; C E Jackson; R J Desnick; E H Schuchman
Journal:  Am J Hum Genet       Date:  1992-04       Impact factor: 11.025

6.  Mucopolysaccharidosis type VII (Sly syndrome). Beta-glucuronidase-deficient mucopolysaccharidosis in the dog.

Authors:  M E Haskins; G D Aguirre; P F Jezyk; E H Schuchman; R J Desnick; D F Patterson
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

7.  Animal model of human disease: Mucopolysaccharidosis VI Maroteaux-Lamy syndrome, Arylsulfatase B-deficient mucopolysaccharidosis in the Siamese cat.

Authors:  M E Haskins; P F Jezyk; R J Desnick; D F Patterson
Journal:  Am J Pathol       Date:  1981-11       Impact factor: 4.307

8.  Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency.

Authors:  E H Birkenmeier; M T Davisson; W G Beamer; R E Ganschow; C A Vogler; B Gwynn; K A Lyford; L M Maltais; C J Wawrzyniak
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

9.  [Clinico-biochemical study on Ishibashi rats (author's transl)].

Authors:  M Takahashi; S Nagase; M Ishibashi
Journal:  Jikken Dobutsu       Date:  1981-10

10.  The pathology of the feline model of mucopolysaccharidosis VI.

Authors:  M E Haskins; G D Aguirre; P F Jezyk; D F Patterson
Journal:  Am J Pathol       Date:  1980-12       Impact factor: 4.307

View more
  26 in total

1.  Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

Authors:  A C Crawley; K H Niedzielski; E L Isaac; R C Davey; S Byers; J J Hopwood
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease.

Authors:  Steven G Potkin; Guia Guffanti; Anita Lakatos; Jessica A Turner; Frithjof Kruggel; James H Fallon; Andrew J Saykin; Alessandro Orro; Sara Lupoli; Erika Salvi; Michael Weiner; Fabio Macciardi
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

Review 3.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

4.  Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.

Authors:  A C Crawley; D A Brooks; V J Muller; B A Petersen; E L Isaac; J Bielicki; B M King; C D Boulter; A J Moore; N L Fazzalari; D S Anson; S Byers; J J Hopwood
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

5.  Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI.

Authors:  M Evers; P Saftig; P Schmidt; A Hafner; D B McLoghlin; W Schmahl; B Hess; K von Figura; C Peters
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 6.  Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.

Authors:  C Vogler; M S Sands; N Galvin; B Levy; C Thorpe; J Barker; W S Sly
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

7.  Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses.

Authors:  Calogera M Simonaro; Yi Ge; Efrat Eliyahu; Xingxuan He; Karl J Jepsen; Edward H Schuchman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

8.  Cell-surface arylsulfatase A and B on sinusoidal endothelial cells, hepatocytes, and Kupffer cells in mammalian livers.

Authors:  Keiko Mitsunaga-Nakatsubo; Shinichiro Kusunoki; Hayato Kawakami; Koji Akasaka; Yoshihiro Akimoto
Journal:  Med Mol Morphol       Date:  2009-06-18       Impact factor: 2.309

9.  Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.

Authors:  Calogera M Simonaro; Marina D'Angelo; Xingxuan He; Efrat Eliyahu; Nataly Shtraizent; Mark E Haskins; Edward H Schuchman
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

10.  Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI.

Authors:  Alessandra Tessitore; Marinella Pirozzi; Alberto Auricchio
Journal:  Pathogenetics       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.